(Q33968782)

30 July 2017

1 reference

title

Recombinant FIXFc: a novel therapy for the royal disease? (English)

1 reference

30 July 2017

Leonard A Valentino

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

22 July 2011

1 reference

Expert Opinion on Biological Therapy

30 July 2017

published in

1 reference

30 July 2017

volume

11

1 reference

30 July 2017

issue

10

1 reference

30 July 2017

page(s)

1361-1368

1 reference

Genomic identification in the historical case of the Nicholas II royal family

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Comparative study of validity of clinical, X-ray and magnetic resonance imaging scores in evaluation and management of haemophilic arthropathy in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Musculoskeletal complications of haemophilia: the joint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Pathogenesis of haemophilic arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Recombinant factor IX for clinical and research use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Consensus recommendations for use of central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Arteriovenous fistula for long-term venous access for boys with hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

The overall effectiveness of prophylaxis in severe haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Practice patterns in haemophilia A therapy -- global progress towards optimal care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Designing CD4 immunoadhesins for AIDS therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Prolonged activity of factor IX as a monomeric Fc fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Cellular processing of bovine factors X and Xa by cultured bovine aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Advances in basic and clinical immunology in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Fc gamma receptor biology and systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Terminal sugars of Fc glycans influence antibody effector functions of IgGs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Validation of a composite score for clinical severity of hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Less severe bleeding in hemophilia B than in hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Barriers to compliance with prophylaxis therapy in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

The economic impact of factor VIII inhibitors in patients with haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Novel drugs to treat hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.603304

10.1517/14712598.2011.603304

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference